

## RESEARCH ARTICLE

# 4G/5G and A-844G Polymorphisms of Plasminogen Activator Inhibitor-1 Associated with Glioblastoma in Iran - a Case-Control Study

Honari Pooyan<sup>1</sup>, Ebrahimi Ahmad<sup>2\*</sup>, Rakhshan Azadeh<sup>3</sup>

## Abstract

**Background:** Glioblastoma is a highly aggressive and malignant brain tumor. Risk factors are largely unknown however, although several biomarkers have been identified which may support development, angiogenesis and invasion of tumor cells. One of these biomarkers is PAI-1. 4G/5G and A-844G are two common polymorphisms in the gene promotor of PAI 1 that may be related to high transcription and expression of this gene. Studies have shown that the prevalence of the 4G and 844G allele is significantly higher in patients with some cancers and genetic disorders. **Materials and Methods:** We here assessed the association of 4G/5G and A-844G polymorphisms with glioblastoma cancer risk in Iranians in a case-control study. All 71 patients with clinically confirmed and 140 volunteers with no history and symptoms of glioblastoma as control group were screened for 4G/5G and A-844G polymorphisms of PAI-1, using ARMS-PCR. Genotype and allele frequencies of case and control groups were analyzed using the DeFinetti program. **Results:** Our results showed significant associations between 4G/5G ( $p=0.01824$ ) and A-844G ( $p = 0.02012$ ) polymorphisms of the PAI-1 gene with glioblastoma cancer risk in our Iranian population. **Conclusions:** The results of this study supporting an association of the PAI-1 4G/5G ( $p=0.01824$ ) and A-844G ( $p = 0.02012$ ) polymorphisms with increasing glioblastoma cancer risk in Iranian patients.

**Keywords:** Biological markers - glioblastoma - plasminogen activator inhibitor 1 - polymorphisms - risk factors

*Asian Pac J Cancer Prev*, 16 (15), 6327-6330

## Introduction

Glioblastoma multiform which grade IV of glioma (according to The World Health Organization classification) is most aggressive primary brain tumor and most deadliest forms of cancer with very poor prognosis, so survival rate of patients is about 1-2 years (Bleeker et al., 2012; Jiang et al., 2012). New studies have found few biomarkers (including MGMT, IDH, TP53, and EGFR and so on) that participated in pathogenesis and prognosis of glioblastoma (Das et al., 2013; McNamara et al., 2013; Serao et al., 2011). Evidences have shown that a high plasma level of plasminogen activator inhibitor-1 (PAI-1) is one of the most biomarkers of a poor prognosis in several cancer types (Dano et al., 2005; Andreassen et al., 2007). In normal Plasma Level, PAI 1 plays some important biological functions specially in cell adhesion and Migration, also PAI 1 can control cell adhesion by regulating of Urokinase plasminogen activator (uPA) and Cell Migration by regulating of Attachment-detachment cycle of Integrins (Binder et al., 2002; Czekay et al., 2011; Yasar Yildiz et al.,

2014). PAI-1 physiological function is not only regulation of uPA, but also plays a crucial role in other biological activities which include: wound healing, atherosclerosis, bone remodeling, rheumatoid arthritis, sepsis, and others (Binder et al., 2002; Gomes-Giacoa et al., 2013). In the other hand studies have shown that any change in gene expression of PAI 1 can have positive effect on tumor cells invasion and development, for example high elevated plasma level of PAI 1 can plays a crucial role in tumor invasion in some type of cancers like colorectal cancer, Breast cancer, liver carcinogenesis and skin carcinogenesis by controlling of degradation of the extracellular matrix by tumor cell-associated proteases (Berger et al., 2002; Dano et al., 2005; Brandal et al., 2011). Moreover Studies have shown increased level of PAI 1 associated with supporting angiogenesis in neuroblastoma tumors and increasing of the risk of developing coronary artery disease as well as the extent of coronary sclerosis, restenosis, myocardial infarction, and it has a protective effect against apoptosis of tumor cells (Bajou et al., 2001; Isogai et al., 2001; Fang et al., 2012). 4G/5G and A-844G polymorphisms are two

<sup>1</sup>Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, <sup>2</sup>Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, <sup>3</sup>Department of Pathology, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran \*For correspondence: ea35m@yahoo.com

common SNPs in gene promotor of PAI 1 that can cause of increasing in PAI 1 gene transcription and expression, in 4G/5G insertion/deletion, one guanine nucleotide deletion at position 675 in this gene promotor can block on of transcriptional repressor, thus the transcription of PAI 1 gene will be higher than wild-type genotype. Besides in A-844G polymorphism, a guanine nucleotide will exchange with adenine nucleotide at position 844 in gene promotor that cause high expression of this gene (Eriksson et al., 1995; Grubic et al., 1996).

The goal of this study was investigating association between 4G/5G and A-844G polymorphisms of PAI 1 with patients affected with GBM in Iranian population.

**Materials and Methods**

Our study population was included of 71 patients with GBM, who were hospitalized in the Shohada-e-Tajrish Specialist Hospital in Tehran (Tehran, Iran). Control group consisted of 140 volunteers who had no symptoms or history of glioblastoma that approved by department of pathology of Shohada-e-Tajrish hospital. Brain Tissue samples were taken by surgery from patients and venous blood samples were taken from all healthy group members. DNA extracted and isolated from Tissue samples by using GeNet Bio PrimePrep Genomic DNA Extraction Kit (GeNet Bio, Korea). DNA obtained and extracted from Blood samples by using Zymo Research Quick-gDNA Blood MiniPrep (Zymo Research, USA). Then Nucleic Acid Quality control, were performed by Nano Drop spectrophotometer.

We have used ARMS-PCR for amplification of polymorphic segments. Three primers (Normal, Mutant and Common) have been designed by using Primer designing tool (NCBI primer designing tools online program). PCR mixture were containing as follow: 6 µL of Taq DNA Polymerase 2x Master Mix RED (Ampliqon), 1.5 µL of DNA samples, 1.5 µL of primer mix (Primer A/B + primer C) + 3 µL of H<sub>2</sub>O added to a final volume of 12 µL.

The ARMS-PCR were performed as following cycles: 95°C for 5 min as primary Denaturation, followed by 30 cycles of 95°C for 35 second as secondary denaturation, 60°C for 35 second for primers annealing, 72°C for 50 second for DNA extension and 72°C for 5 min for final extension (Table 2).then DNA samples (were amplified by ARMS-PCR) have loaded and run on Agarose Gel (3%) Electrophoresis, we have used GEL red for DNA staining. To confirm the results collected by using ARMS-PCR, chosen samples (every seventh) were subjected to DNA sequence analysis. Analysis of our results and genotypes and alleles distribution in case and control groups has calculated by means of DeFinetti program software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) with considering the chi2 square test and the 95% confidence intervals (CI). The level of significance association was set at p<0.05.

**Results**

According to our results, Genotype frequencies of

**Table 1. Genotype Frequency of 4G/5G Polymorphism of PAI-1 in Case and Control Group**

Genotype	Case	Control
4G/4G	21(29.6%)	13(9.3%)
4G/5G	30(42.3%)	84(60%)
5G/5G	20(28.1%)	43(30.7%)
Total	71	140

**Table 2. Genotype Frequency of A-844G Polymorphism of PAI-1 in Case and Control Group**

Genotype	Case	Control
AA	14(19.7%)	5(3.6%)
AG	33(46.5%)	81(57.9%)
GG	24(33.8%)	54(38.5%)
Total	71	140

4G/5G polymorphism showed significant differences in case and control groups (listed in table 1) .in case group genotype frequency were obtained as following: 4G/4G=29.6%, 4G/5G=42.3%, 5G/5G=28.1%.genotype frequency in control group were obtained as following: 4G/4G=9.3%, 4G/5G=60%, 5G/5G=30.7% .This results were showed significantly differences in genotypes and alleles frequency in case and control groups (Table 1, Table 3). According to this results when 5G/5G wild-type genotype exchange to 4G/4G Genotype there is a significant association between mutant genotype with glioblastoma cancer risk (P=0.02523), therefore, it could be suggested that the 4G/4G genotype probably have positive and supportive effect for the glioblastoma cancer risk or the other hand 5G/5G genotype probably have protective/negative effect for the risk of Glioblastoma. Moreover, when if 5G/5G wild-type genotype change to 4G/5G genotype (heterozygous genotype) there is no significant association (P=0.44230), accordingly it seems that 5G allele type have more protective effect than 4G allele's positive and supportive effect for glioblastoma cancer risk in heterozygous genotype.

Otherwise Genotype frequencies of the A-844G polymorphism were generated within the control group as following: AA = 3.6 % AG = 57.9 %, GG = 38.5 %, while the frequencies in the case group were as following: AA=19.7,AG=46.5 and GG= 33.8 % (Table 2).According to this part of our results, if GG wild-type genotype exchange to AA Genotype there is a significant association between mutant genotype with glioblastoma cancer risk (P=0.00059), Thus, it could be suggested that the AA genotype probably have positive and supportive effect for the risk of Glioblastoma development or the other way GG wild-type genotype probably have protective/negative effect for the risk of Glioblastoma (Table 3). Moreover, when if GG wild-type genotype exchange to AG genotype (in heterozygous genotype) there is no significant association (P=0.78611). Therefore, it seems that G allele type have more protective effect than A allele positive and supportive effect for glioblastoma cancer risk in heterozygous genotype.

Table 3. Final Analysis of the Study Results Including Alleles and Genotype Frequency Differences (by means Definetti Program Software)

SNP	Tests for deviation from Hardy-Weinberg equilibrium			Tests for association (C.I.: 95% confidence interval)			Armitage's trend test
	Controls	Cases	allele freq. difference	heterozygous	homozygous	allele positivity	
4G5G	4G5G n11=43 (51.61)	n11=20 (17.25)	[5G]<->[4G] Odds_ratio=1.590 C.I.=[1.058-2.388] chi2=5.01 p=0.02523 (P)	[5G5G]<->[5G4G] Odds_ratio=0.768 C.I.=[0.391-1.508] chi2=0.59 p=0.44230	<b>Risk allele 2</b> [5G5G+]<->[4G4G] Odds_ratio=3.473 C.I.=[1.453-8.304] chi2=8.15 p=0.00430	[5G5G]<->[5G4G+4G4G] Odds_ratio=1.130 C.I.=[0.602-2.122] chi2=0.15 p=0.70265	common odds ratio Odds_ratio=1.758  chi2=5.57 p=0.01824
	n12=84 (66.79)	n12=30 (35.49)					
	n22=13 (21.61)	n22=21 (18.25)					
	f_a1=0.61 +/-0.025	f_a1=0.49 +/-0.045					
	F=-0.25775	F=0.15476					
	p=0.002290 (Pearson)	p=0.192218 (Pearson)					
	p=0.001919 (Llr)	p=0.191332 (Llr)					
	p=0.002712 (Exact)	p=0.234231 (Exact)					
			[4G]<->[5G] Odds_ratio=0.629 C.I.=[0.419-0.945] chi2=5.01 p=0.02523 (P)	[4G4G]<->[5G4G] Odds_ratio=0.221 C.I.=[0.099-0.496] chi2=14.57 p=0.00013	<b>Risk allele 1</b> [4G4G]<->[5G5G] Odds_ratio=0.288 C.I.=[0.120-0.688] chi2=8.15 p=0.00430	[5G5G+5G4G]<->[4G4G] Odds_ratio=0.244 C.I.=[0.113-0.524] chi2=14.35 p=0.00015	common odds ratio Odds_ratio=0.583  chi2=5.57 p=0.01824
			[G]<->[A] Odds_ratio=1.564 C.I.=[1.032-2.371] chi2=4.47 p=0.03447 (P)	[GG]<->[GA] Odds_ratio=0.917 C.I.=[0.489-1.719] chi2=0.07 p=0.78611	<b>Risk allele 2</b> [GG+]<->[AA] Odds_ratio=6.300 C.I.=[2.038-19.477] chi2=11.81 p=0.00059	[GG]<->[GA+AA] Odds_ratio=1.230 C.I.=[0.676-2.236] chi2=0.46 p=0.49775	common odds ratio Odds_ratio=2.059  chi2=5.40 p=0.02012
		[A]<->[G] Odds_ratio=0.639 C.I.=[0.422-0.969] chi2=4.47 p=0.03447 (P)	[AA]<->[GA] Odds_ratio=0.146 C.I.=[0.049-0.436] chi2=14.26 p=0.00016	<b>Risk allele 1</b> [AA]<->[GG] Odds_ratio=0.159 C.I.=[0.051-0.491] chi2=11.81 p=0.00059	[GG+GA]<->[AA] Odds_ratio=0.151 C.I.=[0.052-0.438] chi2=14.99 p=0.00011	common odds ratio Odds_ratio=0.540  chi2=5.40 p=0.02012	

Legend: The tests for association are adapted from Sasieni PD (1997); n11(e): Genotype 11, Wild Genotype (expected); n12(e): Genotype 12 (expected); n22(e): Genotype 22, Mutant Genotype (expected); f\_a1: Frequency of allele 1 +/- standard deviation; F: Inbreeding coefficient; p (Pearson): Pearson's goodness-of-fit chi-square (degree of freedom = 1); p (Llr): Log likelihood ratio chi-square (degree of freedom = 1); p (Exact): Exact test; The following equations correspond to risk allele 2; Odds ratio (allele freq. difference): (Case\_a2 \* Control\_a1) / (Case\_a1 \* Control\_a2); Chi2 (allele freq. difference): (Case\_a2 \* Control\_a1) / (Case\_a1 \* Control\_a2); Chi2 (allele freq. difference): (Case\_a2 \* Control\_a1) / (Case\_a1 \* Control\_a2); Odds ratio (homozygous): (Case\_22 \* Control\_11) / (Case\_11 \* Control\_22); Common odds ratio: ((Case\_12+Case\_22) \* Control\_11) / ((Case\_11 \* Control\_12+Control\_22)); Common odds ratio: (Case\_12\*Control\_11/N01 + Case\_12\*Control\_12/N12 + 4\*(Case\_22\*Control\_11\*N02)); (Case\_11\*Control\_11/N02)); (Case\_11\*Control\_12/N01 + Case\_12\*Control\_22/N12 + 4\*(Case\_22\*Control\_11\*Case\_11\*Control\_22))\*0.5/N02)

## Discussion

A number of potential biomarkers of glioblastoma were identified and classified in last studies, SERPINE1 (PAI 1 gene) is one of these biomarkers (Sreekanthreddy et al., 2010). Many recent studies focused on researching the association polymorphisms of PAI 1 (Especially 4G/5G) with several cancer risks (Wang et al., 2013). For example studied have investigated that 4G/4G genotype will increase breast cancer, Ovarian cancer and colorectal cancer susceptibility, besides this polymorphism will be one cause of poor prognosis of patients in these cancers (Halankova et al., 2013; Ren et al., 2013; Serce et al., 2013). 4G/5G insertion/deletion in gene promotor of PAI 1 will increase transcription of this gene and an exchange of guanine to adenine nucleotide in position 844 of PAI 1 gene will cause of high expression of it. Nonetheless there is a lack of studies about the association of 4G/5G and A-844G polymorphisms of PAI 1 with glioblastoma. For the first time, we have studied the association between 4G/5G and A-844G polymorphisms of plasminogen activator inhibitor 1 with the risk of glioblastoma. Our results have showed the presence of the 4G and A alleles in case group were higher than control group, and there was significantly difference between 4G/4G and AA genotypes frequency in case and control group. Nevertheless it seemed that protective effect of 5G allele is higher than 4G allele effect in heterozygous genotype (4G/5G) thus probably 5G allele has neutralized 5G allele in this genotype, also in A-844G polymorphism presumably G allele has more protective effect against A allele in heterozygous genotype, thus G allele has neutralized A allele effect in this genotype.

In conclusion, the results of this Study supporting an association of the PAI-1 4G/5G ( $p=0.01824$ ) and A-844G ( $p=0.02012$ ) polymorphisms with increasing Glioblastoma cancer risk in Iranian patients.

## References

Andreasen PA (2007). PAI-1 - a potential therapeutic target in cancer. *Curr Drug Targets*, **8**, 1030-41.

Bajou K, Masson V, Gerard RD, et al (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. *J Cell Biol*, **152**, 777-84.

Berger DH (2002). Plasmin/plasminogen system in colorectal cancer. *World J Surg*, **26**, 767-71.

Binder BR, Christ G, Gruber F, et al (2002). Plasminogen activator inhibitor 1: physiological and pathophysiological roles. *News Physiol Sci*, **17**, 56-61.

Bleeker FE, Molenaar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. *J Neurooncol*, **108**, 11-27.

Brandal S, Blake CM, Sullenger BA, et al (2011). Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. *Nucleic Acid Ther*, **21**, 373-81.

Czekay RP, Wilkins-Port CE, Higgins SP, et al (2011). PAI-1: An Integrator of Cell Signaling and Migration. *Int J Cell Biol*, **2011**, 562481.

Dano K, Behrendt N, Hoyer-Hansen G, et al (2005). Plasminogen

activation and cancer. *Thromb Haemost*, **93**, 676-81.

Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. *Asian Pac J Cancer Prev*, **14**, 7261-4.

Eriksson P, Kallin B, van 't Hooft FM, et al (1995). Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. *Proc Natl Acad Sci U S A*, **92**, 1851-5.

Gomes-Giacoia E, Miyake M, Goodison S, et al (2013). Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. *Mol Cancer Ther*, **12**, 2697-708.

Grubic N, Stegnar M, Peternel P, et al (1996). A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. *Thromb Res*, **84**, 431-43.

Halankova J, Kiss I, Pavlovsky Z, et al (2013). Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. *Neoplasma*, **60**, 151-9.

Isogai C, Laug WE, Shimada H, et al (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. *Cancer Res*, **61**, 5587-94.

Jiang Y, Uhrbom L (2012). On the origin of glioma. *Ups J Med Sci*, **117**, 113-21.

McNamara MG, Sahebjam S, Mason WP (2013). Emerging biomarkers in glioblastoma. *Cancers (Basel)*, **5**, 1103-19.

Ren F, Shi H, Zhang G, et al (2013). Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. *J Exp Clin Cancer Res*, **32**, 60.

Serao NV, Delfino KR, Southey BR, et al (2011). Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. *BMC Med Genomics*, **4**, 49.

Serce NB, Boesl A, Klaman I, et al (2012). Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. *BMC Cancer*, **12**, 597.

Sreekanthreddy P, Srinivasan H, Kumar DM, et al (2010). Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. *Cancer Epidemiol Biomarkers Prev*, **19**, 1409-22.

Wang S, Cao Q, Wang X, et al (2013). PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis. *PLoS One*, **8**, 56797.

Yasar Yildiz S, Kuru P, Toksoy Oner E, et al (2014). Functional stability of plasminogen activator inhibitor-1. *Scientific World J*, **2014**, 858293.